NO20042833L - Vaksine og fremgangsmate for behandling av motorneuronale lidelser - Google Patents

Vaksine og fremgangsmate for behandling av motorneuronale lidelser

Info

Publication number
NO20042833L
NO20042833L NO20042833A NO20042833A NO20042833L NO 20042833 L NO20042833 L NO 20042833L NO 20042833 A NO20042833 A NO 20042833A NO 20042833 A NO20042833 A NO 20042833A NO 20042833 L NO20042833 L NO 20042833L
Authority
NO
Norway
Prior art keywords
cop
vaccine
neuronal disorders
treating motor
tyr
Prior art date
Application number
NO20042833A
Other languages
English (en)
Other versions
NO336231B1 (no
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20042833L publication Critical patent/NO20042833L/no
Publication of NO336231B1 publication Critical patent/NO336231B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20042833A 2001-12-06 2004-07-05 Anvendelse av Cop-1 for fremstilling av en vaksine for behandling av amyotrofisk lateral sklerose (ALS). NO336231B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en) 2001-12-06 2002-12-05 Vaccine and method for treatment of motor neurone diseases

Publications (2)

Publication Number Publication Date
NO20042833L true NO20042833L (no) 2004-08-12
NO336231B1 NO336231B1 (no) 2015-06-22

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042833A NO336231B1 (no) 2001-12-06 2004-07-05 Anvendelse av Cop-1 for fremstilling av en vaksine for behandling av amyotrofisk lateral sklerose (ALS).

Country Status (23)

Country Link
US (1) US7351686B2 (no)
EP (1) EP1429800B1 (no)
JP (1) JP4542339B2 (no)
KR (1) KR20040081431A (no)
CN (2) CN1617736A (no)
AT (1) ATE422362T1 (no)
AU (1) AU2002353486B2 (no)
CA (1) CA2469092C (no)
CY (1) CY1109044T1 (no)
DE (1) DE60231131D1 (no)
DK (1) DK1429800T3 (no)
ES (1) ES2322566T3 (no)
HU (1) HU228207B1 (no)
IL (1) IL160105A0 (no)
IS (1) IS2670B (no)
MX (1) MXPA04005537A (no)
NO (1) NO336231B1 (no)
NZ (1) NZ533356A (no)
PL (1) PL205469B1 (no)
PT (1) PT1429800E (no)
RU (1) RU2303996C2 (no)
SI (1) SI1429800T1 (no)
WO (1) WO2003047500A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
CA2548310C (en) 2003-12-09 2014-02-18 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
CA2558380A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
RU2410115C2 (ru) * 2004-05-07 2011-01-27 Пептиммьюн, Инк. Способы лечения заболеваний с помощью статистических сополимеров
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2615506A1 (en) * 2005-07-15 2007-01-25 Novartis Ag Pamps, pathogen associated molecular patterns
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013084236A1 (en) * 2011-12-05 2013-06-13 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als)
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
US20150238582A1 (en) 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) * 1996-09-27 2003-09-10 Гилфорд Фармасьютикалз Инк. Способ лечения глутаматных расстройств
AU2868699A (en) * 1998-02-13 1999-08-30 Autoimmune, Inc. Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1039929A1 (en) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
EP1248643B1 (en) * 2000-01-20 2005-08-17 YEDA RESEARCH AND DEVELOPMENT Co. LTD. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
DE60116467T2 (de) * 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
SI1429800T1 (sl) 2009-08-31
PL205469B1 (pl) 2010-04-30
CN1617736A (zh) 2005-05-18
WO2003047500A2 (en) 2003-06-12
WO2003047500A3 (en) 2004-03-18
NZ533356A (en) 2006-10-27
DE60231131D1 (de) 2009-03-26
EP1429800A2 (en) 2004-06-23
RU2004120536A (ru) 2005-03-27
EP1429800A4 (en) 2006-03-22
DK1429800T3 (da) 2009-04-27
JP2005515198A (ja) 2005-05-26
NO336231B1 (no) 2015-06-22
ATE422362T1 (de) 2009-02-15
PT1429800E (pt) 2009-04-27
ES2322566T3 (es) 2009-06-23
MXPA04005537A (es) 2004-11-01
RU2303996C2 (ru) 2007-08-10
CA2469092C (en) 2013-02-19
PL370070A1 (en) 2005-05-16
CA2469092A1 (en) 2003-06-12
HUP0500039A2 (hu) 2005-03-29
HUP0500039A3 (en) 2010-01-28
EP1429800B1 (en) 2009-02-11
CN102151330B (zh) 2017-04-12
HK1067043A1 (en) 2005-04-01
CY1109044T1 (el) 2014-07-02
IS7296A (is) 2004-06-03
AU2002353486B2 (en) 2009-01-15
AU2002353486A1 (en) 2003-06-17
KR20040081431A (ko) 2004-09-21
US7351686B2 (en) 2008-04-01
CN102151330A (zh) 2011-08-17
US20050220802A1 (en) 2005-10-06
JP4542339B2 (ja) 2010-09-15
IL160105A0 (en) 2004-06-20
HU228207B1 (hu) 2013-01-28
IS2670B (is) 2010-09-15

Similar Documents

Publication Publication Date Title
EP1429800A4 (en) VACCINE AND METHOD FOR THE TREATMENT OF MOTOR NEURONAL DISEASES
EA200601132A1 (ru) Предупреждение и лечение амилоидогенного заболевания
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU1879697A (en) Peptide immunogens for vaccination against and treatment of allergy
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
EP1040830A4 (en) MEDICINE FOR NEURODEGENERATIVE DISEASES
BG105575A (en) Method and agent for the treatment of cerebral ischaemia
EP2279742A3 (en) Combinations for the treatment of immunoinflammatory disorders
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
SE9603725D0 (sv) New teatment
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
EP0744176A3 (en) Methods for inhibiting bone loss
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
DE60223564D1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
WO2003045322A3 (en) Method for treating and preventing pancreatitis
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
EP0579765A4 (en) Method and composition for the treatment of herpes related disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees